Stay updated on SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial

Sign up to get notified when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    0.7%
    Check dated 2025-07-05T04:26:11.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The web page has updated its date listings, adding new dates in June 2025 while removing older dates from May 2025.
    Difference
    0.4%
    Check dated 2025-06-28T01:01:16.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.6%
    Check dated 2025-06-20T20:24:28.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.1%
    Check dated 2025-06-13T16:20:04.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect new results and timelines for a clinical study involving Sacituzumab Govitecan and Pembrolizumab in HR+ / HER2- metastatic breast cancer, with a new data cutoff date and revised reporting dates.
    Difference
    12%
    Check dated 2025-06-06T09:48:26.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    0.9%
    Check dated 2025-05-30T04:46:29.000Z thumbnail image

Stay in the know with updates to SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.